GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B2243 Almotriptan MalateSummary: 5-HT1B/1D-receptor agonist -
B7435 (±)-5'-Chloro-5'-deoxy-ENBASummary: adenosine A1 receptor agonist, selective and high-affinity -
C5509 S-1 MethanandamideSummary: CB1 receptor ligand -
B1356 Detomidine HClSummary: Adrenergic receptor agonist -
B2242 Urapidil HClSummary: α1-adrenoceptor antagonist and 5-HT1A receptor agonist -
B7373 SLV 320Summary: adenosine A1 receptor antagonist -
C5311 NESS 0327Summary: extremely potent cannabinoid (CB) receptor antagonist -
B2241 OndansetronTarget: 5-HT3 ReceptorsSummary: serotonin 5-HT3 receptor antagonist -
B1355 Cisatracurium BesylateTarget: AcetylcholineSummary: Neuromuscular-blocking drug -
B7355 8-(3-Chlorostyryl)caffeineSummary: adenosine A2A receptor antagonist and MAO-B inhibitor
